TimesSquare Capital Management LLC Increases Stake in Vericel Corporation $VCEL

TimesSquare Capital Management LLC increased its stake in Vericel Corporation (NASDAQ:VCEL) by 13.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 743,389 shares of the biotechnology company’s stock after buying an additional 90,924 shares during the period. TimesSquare Capital Management LLC’s holdings in Vericel were worth $31,631,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Ameritas Advisory Services LLC purchased a new position in shares of Vericel during the 2nd quarter worth approximately $30,000. CWM LLC grew its holdings in shares of Vericel by 101.3% during the second quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 694 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Vericel during the second quarter valued at approximately $60,000. Gagnon Securities LLC purchased a new position in Vericel in the 1st quarter worth approximately $137,000. Finally, US Bancorp DE raised its holdings in Vericel by 29.9% in the 1st quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 706 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have commented on VCEL shares. Zacks Research upgraded Vericel from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Truist Financial reiterated a “buy” rating and issued a $50.00 price objective (up from $41.00) on shares of Vericel in a report on Monday. BTIG Research lowered Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Weiss Ratings raised shares of Vericel from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday. Finally, Canaccord Genuity Group reduced their price target on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.20.

Vericel Stock Up 5.3%

Vericel stock opened at $41.05 on Wednesday. Vericel Corporation has a 52-week low of $29.24 and a 52-week high of $63.00. The company has a market cap of $2.08 billion, a P/E ratio of 342.11 and a beta of 1.41. The business has a 50-day simple moving average of $33.96 and a two-hundred day simple moving average of $37.70.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12. The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $64.57 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.02) earnings per share. Vericel has set its FY 2025 guidance at EPS. Research analysts anticipate that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.